Literature DB >> 14973383

Xenograft models of premalignant breast disease.

F R Miller1.   

Abstract

Dysplastic and hyperplastic proliferative lesions with graded severity of atypia are recognized in a number of tissues and are generally suspected to be premalignant, that is to say at high risk for further progressing to carcinoma in situ and invasive cancer. However, few xenograft models of premalignancy for any organ site have been successfully developed. A good model of human premalignant breast disease would lead to lesions which resemble high risk human breast disease in xenografts and sporadically progress to invasive cancer with time. In this chapter the use of breast tissue pieces and epithelial cells for establishment of xenografts and the development of human breast epithelial cell lines that form premalignant xenograft lesions are described. MCF10AT cells not only form simple differentiated ducts which persist in xenografts and sporadically progress to carcinoma, but also form intermediate proliferative lesions resembling proliferative disease without atypia, atypical hyperplasia, and carcinoma in situ.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 14973383     DOI: 10.1023/a:1009577811584

Source DB:  PubMed          Journal:  J Mammary Gland Biol Neoplasia        ISSN: 1083-3021            Impact factor:   2.673


  70 in total

1.  Rapid screening of protein profiles of human breast cancer cell lines using non-porous reversed-phase high performance liquid chromatography separation with matrix-assisted laser desorption/ionization time-of-flight mass spectral analysis.

Authors:  B E Chong; D M Lubman; F R Miller; A J Rosenspire
Journal:  Rapid Commun Mass Spectrom       Date:  1999       Impact factor: 2.419

2.  Two types of normal human breast epithelial cells derived from reduction mammoplasty: phenotypic characterization and response to SV40 transfection.

Authors:  C Y Kao; K Nomata; C S Oakley; C W Welsch; C C Chang
Journal:  Carcinogenesis       Date:  1995-03       Impact factor: 4.944

3.  Activated c-Ha-ras is not sufficient to produce the preneoplastic phenotype of human breast cell line MCF10AT.

Authors:  F R Miller; R J Pauley; B Wang
Journal:  Anticancer Res       Date:  1996 Jul-Aug       Impact factor: 2.480

4.  Cell proliferation in the human mammary epithelium. Differential contribution by epithelial and myoepithelial cells.

Authors:  K Joshi; J A Smith; N Perusinghe; P Monoghan
Journal:  Am J Pathol       Date:  1986-08       Impact factor: 4.307

5.  Long-term explant culture of normal mammary epithelium.

Authors:  E A Hillman; M G Valerio; S A Halter; L A Barrett-Boone; B F Trump
Journal:  Cancer Res       Date:  1983-01       Impact factor: 12.701

6.  P53-independent induction of p21(waf1) pathway is preserved during tumor progression.

Authors:  Y Chen; S Cipriano; F Sarkar; J Ware; J Arenkiel
Journal:  Int J Oncol       Date:  1995-10       Impact factor: 5.650

7.  Altered P53 conformation.

Authors:  P Shekhar; R Welte; J Christman; H Wang; J Werdell
Journal:  Int J Oncol       Date:  1997-11       Impact factor: 5.650

8.  The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone.

Authors:  I J Laidlaw; R B Clarke; A Howell; A W Owen; C S Potten; E Anderson
Journal:  Endocrinology       Date:  1995-01       Impact factor: 4.736

9.  Transplantation of human tumors in nude mice.

Authors:  Y Shimosato; T Kameya; K Nagai; S Hirohashi; T Koide; H Hayashi; T Nomura
Journal:  J Natl Cancer Inst       Date:  1976-06       Impact factor: 13.506

10.  Detection of c-erbB-2 mRNAs using dig-labelled oligonucleotide probe with in situ hybridisation in human breast carcinoma: comparison with immunohistochemical results.

Authors:  M Oztürk; S Bolkent; S Yilmazer; G Kaner; H Unal
Journal:  Anal Cell Pathol       Date:  1998       Impact factor: 2.916

View more
  52 in total

1.  Synthetic triterpenoids can protect against toxicity without reducing the efficacy of treatment with Carboplatin and Paclitaxel in experimental lung cancer.

Authors:  Karen T Liby
Journal:  Dose Response       Date:  2013-08-01       Impact factor: 2.658

2.  Antagonists of anaphase-promoting complex (APC)-2-cell cycle and apoptosis regulatory protein (CARP)-1 interaction are novel regulators of cell growth and apoptosis.

Authors:  Vineshkumar Thidil Puliyappadamba; Wenjuan Wu; Debra Bevis; Liyue Zhang; Lisa Polin; Robert Kilkuskie; Russell L Finley; Scott D Larsen; Edi Levi; Fred R Miller; Anil Wali; Arun K Rishi
Journal:  J Biol Chem       Date:  2011-09-08       Impact factor: 5.157

3.  Identification of a PEAK1/ZEB1 signaling axis during TGFβ/fibronectin-induced EMT in breast cancer.

Authors:  Megan Agajanian; Farhana Runa; Jonathan A Kelber
Journal:  Biochem Biophys Res Commun       Date:  2015-08-20       Impact factor: 3.575

Review 4.  Breast cancer complexity: implications of intratumoral heterogeneity in clinical management.

Authors:  Brittany Haynes; Ashapurna Sarma; Pratima Nangia-Makker; Malathy P Shekhar
Journal:  Cancer Metastasis Rev       Date:  2017-09       Impact factor: 9.264

5.  Differential Expression of Key Signaling Proteins in MCF10 Cell Lines, a Human Breast Cancer Progression Model.

Authors:  Jae Young So; Hong Jin Lee; Pavel Kramata; Audrey Minden; Nanjoo Suh
Journal:  Mol Cell Pharmacol       Date:  2012-01-01

6.  Regulation of in situ to invasive breast carcinoma transition.

Authors:  Min Hu; Jun Yao; Danielle K Carroll; Stanislawa Weremowicz; Haiyan Chen; Daniel Carrasco; Andrea Richardson; Shelia Violette; Tatiana Nikolskaya; Yuri Nikolsky; Erica L Bauerlein; William C Hahn; Rebecca S Gelman; Craig Allred; Mina J Bissell; Stuart Schnitt; Kornelia Polyak
Journal:  Cancer Cell       Date:  2008-05       Impact factor: 31.743

7.  Proteome-wide profiling of the MCF10AT breast cancer progression model.

Authors:  Lee Yee Choong; Simin Lim; Poh Kuan Chong; Chow Yin Wong; Nilesh Shah; Yoon Pin Lim
Journal:  PLoS One       Date:  2010-06-09       Impact factor: 3.240

8.  Pin1 regulates the dynamics of c-Myc DNA binding to facilitate target gene regulation and oncogenesis.

Authors:  Amy S Farrell; Carl Pelz; Xiaoyan Wang; Colin J Daniel; Zhiping Wang; Yulong Su; Mahnaz Janghorban; Xiaoli Zhang; Charlie Morgan; Soren Impey; Rosalie C Sears
Journal:  Mol Cell Biol       Date:  2013-05-28       Impact factor: 4.272

Review 9.  Next-generation sequencing: a powerful tool for the discovery of molecular markers in breast ductal carcinoma in situ.

Authors:  Hitchintan Kaur; Shihong Mao; Seema Shah; David H Gorski; Stephen A Krawetz; Bonnie F Sloane; Raymond R Mattingly
Journal:  Expert Rev Mol Diagn       Date:  2013-03       Impact factor: 5.225

10.  An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ.

Authors:  Fariba Behbod; Frances S Kittrell; Heather LaMarca; David Edwards; Sofia Kerbawy; Jessica C Heestand; Evelin Young; Purna Mukhopadhyay; Hung-Wen Yeh; D Craig Allred; Min Hu; Kornelia Polyak; Jeffrey M Rosen; Daniel Medina
Journal:  Breast Cancer Res       Date:  2009       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.